Does very high power, short duration (vHPSD) ablation demonstrate clinical feasibility and safety in patients with paroxysmal atrial fibrillation?
First-in-human evidence shows that very high power, short duration ablation with a novel temperature-controlled catheter is feasible and safe for paroxysmal AF, potentially reducing procedure times.
This first-in-human study of a novel catheter with optimized temperature control demonstrated the clinical feasibility and safety of vHPSD ablation. Procedure and fluoroscopy times were substantially lower than historical standard ablation with point-by-point catheters. (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation QDOT-FAST; NCT03459196).
Reddy et al. (2019) studied this question.